Daily Stock Analysis, ASMB, Assembly Biosciences Inc, priceseries

Assembly Biosciences Inc. Daily Stock Analysis
Stock Information
Open
15.29
Close
15.61
High
15.79
Low
14.91
Previous Close
15.21
Daily Price Gain
0.40
YTD High
25.68
YTD High Date
Jan 7, 2019
YTD Low
13.13
YTD Low Date
Apr 15, 2019
YTD Price Change
-7.43
YTD Gain
-32.25%
52 Week High
48.91
52 Week High Date
Jun 19, 2018
52 Week Low
13.13
52 Week Low Date
Apr 15, 2019
52 Week Price Change
-28.10
52 Week Gain
-64.29%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 12. 2017
13.79
Feb 10. 2017
19.80
20 Trading Days
43.58%
Link
LONG
Jul 28. 2017
21.78
Oct 12. 2017
34.52
53 Trading Days
58.52%
Link
LONG
Nov 16. 2017
34.95
Dec 7. 2017
42.63
14 Trading Days
21.98%
Link
LONG
Feb 13. 2018
47.92
Mar 5. 2018
56.49
13 Trading Days
17.88%
Link
Company Information
Stock Symbol
ASMB
Exchange
NasdaqCM
Company URL
http://www.assemblybio.com
Company Phone
(212) 554-4388
CEO
Derek A. Small
Headquarters
Indiana
Business Address
11711 N. MERIDIAN STREET, SUITE 310, CARMEL, IN 46032
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001426800
About

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics designed to restore health to a dysbiotic microbiome. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.

Description

Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its lead product candidate from the platform is AB-M101 that has been completed Phase Ia clinical trial to treat clostridium difficile infections. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.